vs

Side-by-side financial comparison of Brookfield Asset Management Ltd. (BAM) and Insulet Corporation (PODD). Click either name above to swap in a different company.

Brookfield Asset Management Ltd. is the larger business by last-quarter revenue ($1.1B vs $783.7M, roughly 1.4× Insulet Corporation). Brookfield Asset Management Ltd. runs the higher net margin — 56.7% vs 13.0%, a 43.7% gap on every dollar of revenue.

Brookfield Asset Management Ltd. is a Canadian-American alternative asset manager. The company was founded in December 2022 as a spin-off of the asset management operations of Brookfield Corporation, and manages investments across real estate, infrastructure, renewable energy, private equity, and credit markets globally.

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.

BAM vs PODD — Head-to-Head

Bigger by revenue
BAM
BAM
1.4× larger
BAM
$1.1B
$783.7M
PODD
Higher net margin
BAM
BAM
43.7% more per $
BAM
56.7%
13.0%
PODD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BAM
BAM
PODD
PODD
Revenue
$1.1B
$783.7M
Net Profit
$615.0M
$101.6M
Gross Margin
72.6%
Operating Margin
84.2%
18.7%
Net Margin
56.7%
13.0%
Revenue YoY
31.2%
Net Profit YoY
0.9%
EPS (diluted)
$1.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAM
BAM
PODD
PODD
Q4 25
$1.1B
$783.7M
Q3 25
$974.0M
$706.3M
Q2 25
$931.0M
$649.1M
Q1 25
$954.0M
$569.0M
Q4 24
$597.5M
Q3 24
$873.0M
$543.9M
Q2 24
$821.0M
$488.5M
Q1 24
$786.0M
$441.7M
Net Profit
BAM
BAM
PODD
PODD
Q4 25
$615.0M
$101.6M
Q3 25
$692.0M
$87.6M
Q2 25
$584.0M
$22.5M
Q1 25
$507.0M
$35.4M
Q4 24
$100.7M
Q3 24
$537.0M
$77.5M
Q2 24
$124.0M
$188.6M
Q1 24
$373.0M
$51.5M
Gross Margin
BAM
BAM
PODD
PODD
Q4 25
72.6%
Q3 25
72.2%
Q2 25
69.7%
Q1 25
71.9%
Q4 24
72.1%
Q3 24
69.3%
Q2 24
67.7%
Q1 24
69.5%
Operating Margin
BAM
BAM
PODD
PODD
Q4 25
84.2%
18.7%
Q3 25
79.1%
16.7%
Q2 25
70.8%
18.7%
Q1 25
61.0%
15.6%
Q4 24
18.3%
Q3 24
72.5%
16.2%
Q2 24
80.4%
11.2%
Q1 24
56.5%
12.9%
Net Margin
BAM
BAM
PODD
PODD
Q4 25
56.7%
13.0%
Q3 25
71.0%
12.4%
Q2 25
62.7%
3.5%
Q1 25
53.1%
6.2%
Q4 24
16.9%
Q3 24
61.5%
14.2%
Q2 24
15.1%
38.6%
Q1 24
47.5%
11.7%
EPS (diluted)
BAM
BAM
PODD
PODD
Q4 25
$1.42
Q3 25
$1.24
Q2 25
$0.32
Q1 25
$0.50
Q4 24
$1.38
Q3 24
$1.08
Q2 24
$2.59
Q1 24
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAM
BAM
PODD
PODD
Cash + ST InvestmentsLiquidity on hand
$1.6B
Total DebtLower is stronger
$930.8M
Stockholders' EquityBook value
$8.9B
$1.5B
Total Assets
$17.0B
$3.2B
Debt / EquityLower = less leverage
0.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAM
BAM
PODD
PODD
Q4 25
$1.6B
Q3 25
$1.1B
Q2 25
$480.0M
Q1 25
$332.0M
Q4 24
Q3 24
Q2 24
$10.0M
Q1 24
Total Debt
BAM
BAM
PODD
PODD
Q4 25
$930.8M
Q3 25
$934.9M
Q2 25
$939.0M
Q1 25
$1.6B
Q4 24
$1.3B
Q3 24
$1.4B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
BAM
BAM
PODD
PODD
Q4 25
$8.9B
$1.5B
Q3 25
$8.5B
$1.4B
Q2 25
$8.5B
$1.5B
Q1 25
$8.5B
$1.3B
Q4 24
$1.2B
Q3 24
$9.0B
$1.1B
Q2 24
$3.2B
$998.4M
Q1 24
$2.2B
$790.7M
Total Assets
BAM
BAM
PODD
PODD
Q4 25
$17.0B
$3.2B
Q3 25
$16.5B
$3.0B
Q2 25
$16.1B
$3.5B
Q1 25
$15.0B
$3.5B
Q4 24
$3.1B
Q3 24
$3.0B
Q2 24
$4.2B
$2.9B
Q1 24
$2.6B
Debt / Equity
BAM
BAM
PODD
PODD
Q4 25
0.61×
Q3 25
0.68×
Q2 25
0.64×
Q1 25
1.21×
Q4 24
1.07×
Q3 24
1.21×
Q2 24
1.36×
Q1 24
1.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAM
BAM
PODD
PODD
Operating Cash FlowLast quarter
$562.0M
$183.3M
Free Cash FlowOCF − Capex
$48.2M
FCF MarginFCF / Revenue
6.2%
Capex IntensityCapex / Revenue
17.2%
Cash ConversionOCF / Net Profit
0.91×
1.80×
TTM Free Cash FlowTrailing 4 quarters
$377.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAM
BAM
PODD
PODD
Q4 25
$562.0M
$183.3M
Q3 25
$745.0M
$125.7M
Q2 25
$529.0M
$196.5M
Q1 25
$265.0M
$63.8M
Q4 24
$147.7M
Q3 24
$567.0M
$98.5M
Q2 24
$159.0M
$96.5M
Q1 24
$516.0M
$87.6M
Free Cash Flow
BAM
BAM
PODD
PODD
Q4 25
$48.2M
Q3 25
$100.1M
Q2 25
$177.9M
Q1 25
$51.5M
Q4 24
$94.1M
Q3 24
$71.8M
Q2 24
$74.0M
Q1 24
$65.5M
FCF Margin
BAM
BAM
PODD
PODD
Q4 25
6.2%
Q3 25
14.2%
Q2 25
27.4%
Q1 25
9.1%
Q4 24
15.7%
Q3 24
13.2%
Q2 24
15.1%
Q1 24
14.8%
Capex Intensity
BAM
BAM
PODD
PODD
Q4 25
17.2%
Q3 25
3.6%
Q2 25
2.9%
Q1 25
2.2%
Q4 24
9.0%
Q3 24
4.9%
Q2 24
4.6%
Q1 24
5.0%
Cash Conversion
BAM
BAM
PODD
PODD
Q4 25
0.91×
1.80×
Q3 25
1.08×
1.43×
Q2 25
0.91×
8.73×
Q1 25
0.52×
1.80×
Q4 24
1.47×
Q3 24
1.06×
1.27×
Q2 24
1.28×
0.51×
Q1 24
1.38×
1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BAM
BAM

Incentive Fees$452.0M42%
Infrastruture$332.0M31%
Private Equity$174.0M16%
Renewable Power And Transition$66.0M6%
Other$47.0M4%
Management And Advisory Fees$14.0M1%

PODD
PODD

U.S.Omnipod$567.8M72%
International Omnipod$214.0M27%
Drug Delivery$1.9M0%

Related Comparisons